Joint Tuberculosis

Medical Disclaimer: This information is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their own independent medical judgment in the context of individual patient circumstances and available evidence. Dosages and guidelines may vary and should be verified with the latest prescribing information and local protocols.

Overview

• Definition: Joint tuberculosis (TB), also known as osteoarticular TB or skeletal TB, is an extrapulmonary manifestation of Mycobacterium tuberculosis infection that affects the bones and joints. It typically results from hematogenous dissemination from a primary focus, most commonly in the lungs, but can also arise from lymphatic spread or direct extension. Pott's disease specifically refers to TB of the spine.
• Epidemiology:
  • Skeletal TB accounts for approximately 1-5% of all TB cases, but up to 10-35% of extrapulmonary TB cases.
  • Its prevalence is higher in regions endemic for tuberculosis and in populations with high rates of HIV infection or other immunocompromising conditions.
  • It can affect all age groups but is more common in children and young adults in some developing countries, while in developed countries, it may be seen more in older adults or immunocompromised individuals.
  • The spine (Pott's disease) is the most commonly affected site (approximately 50% of skeletal TB cases), followed by large weight-bearing joints like the hip and knee.
• Classification:
  • By site:
    • Spinal TB (Pott's disease): Most common, affecting vertebral bodies, leading to collapse, kyphosis (gibbus deformity), and neurological deficits.
    • Peripheral Joint TB: Hip, knee, ankle, elbow, shoulder, wrist, sacroiliac joint. Typically monoarticular.
    • Bone TB: Osteomyelitis without primary joint involvement (e.g., long bones, ribs, small bones).
    • Tenosynovitis/Bursitis: Inflammation of tendon sheaths or bursae due to TB.
  • By pathology: Synovial TB (early stage, primarily affects synovium) vs. Osseous TB (involves bone directly or secondary to synovial infection).

Pathophysiology

• Mechanism:
  1. Hematogenous Dissemination: The most common route. M. tuberculosis bacilli from a primary focus (usually pulmonary, but can be lymph node, gastrointestinal, or genitourinary) enter the bloodstream.
  2. Seeding: The bacilli preferentially seed in highly vascularized areas of bones or synovial membranes. In long bones, this often occurs in the metaphyseal or epiphyseal regions. In the spine, the anterior aspects of vertebral bodies are common sites.
  3. Inflammatory Response: Initial infection leads to a subacute or chronic inflammatory reaction, characterized by granuloma formation (epithelioid cells, lymphocytes, Langhans giant cells).
  4. Caseous Necrosis: Central part of the granuloma undergoes caseous necrosis, forming a cheesy, avascular material. This provides a suitable environment for mycobacterial growth and protects them from immune cells and drug penetration.
  5. Bone/Cartilage Destruction: Enzymes released from inflammatory cells, coupled with the expanding caseous material, lead to progressive destruction of bone (osteolysis) and articular cartilage. This can cause joint space narrowing, erosions, and eventually joint collapse or pathological fractures.
  6. Cold Abscess Formation: Caseous material and purulent exudate can track along fascial planes, forming a "cold abscess" (non-tender, without significant erythema or warmth). These can rupture externally as sinus tracts.
  7. Spinal TB Specifics: Infection often starts in the anterior part of the vertebral body, spreads under the anterior longitudinal ligament to adjacent vertebrae, involves the intervertebral disc (unlike pyogenic infection which primarily affects disc space), and can lead to vertebral collapse, kyphosis, and spinal cord compression.
• Risk Factors:
  • Immunosuppression:
    • HIV infection (strongest risk factor)
    • Long-term corticosteroid use
    • TNF-alpha inhibitor therapy
    • Organ transplantation
    • Malignancy (especially hematological)
    • Diabetes mellitus
    • Chronic renal failure
    • Malnutrition
  • Close contact with active TB cases: Especially pulmonary TB.
  • Previous history of TB: Suggests latent infection or previous inadequate treatment.
  • Geographic origin: From high TB-burden countries.
  • Socioeconomic factors: Overcrowding, poor sanitation, poverty, homelessness.
  • Substance abuse: Alcoholism, intravenous drug use.
• Protective Factors:
  • Robust immune system: Competent cellular immunity is crucial for containing TB infection.
  • Good nutrition: Supports overall immune function.
  • BCG vaccination: While primarily protective against severe forms of TB in children (e.g., miliary TB, TB meningitis), its efficacy against pulmonary and some extrapulmonary forms like bone/joint TB in adults is variable and less certain. It is not considered a primary preventative for joint TB itself.
  • Early detection and treatment of latent TB infection (LTBI): For high-risk individuals, LTBI treatment can prevent progression to active disease, including joint TB.

Clinical Presentation

Signs and Symptoms

Joint TB often has an insidious onset, with symptoms evolving over weeks to months, making diagnosis challenging and often delayed. - Cardinal Features: - Pain: Most common symptom, often localized, dull ache, insidious onset, progressive. Characteristically worse at night or with activity, may improve slightly with rest. Can be referred (e.g., hip TB referring pain to knee). - Swelling: Usually localized, firm or boggy, often "cold" (without significant warmth or erythema), due to synovial effusion or soft tissue swelling. - Stiffness: Particularly morning stiffness, improving with activity, similar to inflammatory arthritis, but often more persistent. - Limited Range of Motion (ROM): Painful and progressively restricted in all planes due to inflammation, effusion, muscle spasm, and later, bony destruction/ankylosis. - Constitutional Symptoms: Weight loss, fatigue, low-grade fever (especially evening), night sweats, anorexia. These are present in about 30-50% of cases but may be absent in isolated joint TB. - Early Signs: - Mild, non-specific joint pain with insidious onset. - Subtle swelling or tenderness. - Mild limitation of specific movements. - Often mistaken for sprain, bursitis, or other rheumatic conditions. - Advanced Signs: - Deformity: Progressive joint destruction leading to angulation, subluxation, or dislocation. In spinal TB, severe kyphosis (gibbus deformity) or scoliosis. - Muscle atrophy: Due to disuse and pain. - Cold Abscess: A palpable, fluctuant, non-tender mass (e.g., psoas abscess in spinal TB, gluteal abscess in hip TB). - Sinus Tract Formation: If a cold abscess ruptures externally, forming a chronic draining sinus. This is highly suggestive of osteomyelitis, often TB. - Neurological Deficits (Spinal TB): Radiculopathy, myelopathy (e.g., paraparesis, paraplegia), sensory loss, bowel/bladder dysfunction due to spinal cord compression. This is a severe complication. - Pathological Fractures: In weakened bones. - Limb Length Discrepancy: Due to growth plate involvement in children, or joint destruction/collapse. - Atypical Presentations: - Acute presentation: Rarely, may present acutely with features mimicking septic arthritis (fever, warmth, marked pain, rapid destruction). - Polyarticular involvement: Very rare (2-10% of cases), making diagnosis difficult as it can mimic inflammatory arthropathies (e.g., rheumatoid arthritis). - Tenosynovitis or bursitis: Without obvious joint involvement, but can progress to involve adjacent joint. - Dactylitis: Swelling of short bones in hands/feet (e.g., spina ventosa). - Absence of constitutional symptoms or pulmonary TB: Making diagnosis challenging.

Physical Examination

• Inspection:
  • Swelling: Localized, firm, boggy, or fluctuant (abscess). May be subtle.
  • Erythema: Usually absent or minimal ("cold" inflammation).
  • Deformity: Joint angulation, subluxation, fixed flexion deformity. In spinal TB, kyphosis, gibbus.
  • Skin changes: Scarring, sinus tracts, overlying skin thinning or discoloration.
  • Muscle atrophy: Around affected joint or limb.
• Palpation:
  • Tenderness: Localized over the joint line or bony prominences.
  • Warmth: Usually absent or mild.
  • Effusion: Palpable fluid in the joint (e.g., knee effusion).
  • Crepitus: May be felt with movement due to cartilage destruction.
  • Bony irregularities: Due to erosions or osteophytes (if chronic).
  • Soft tissue swelling: Thickening of synovium.
  • Cold abscess: Fluctuant, non-tender swelling away from the joint (e.g., psoas mass, gluteal mass).
• Special Tests:
  • Range of Motion (ROM): Assess active and passive ROM. Typically painful and restricted in all planes (unlike mechanical issues which might spare certain movements). Early flexion contracture is common.
  • Gait assessment: Antalgic gait if weight-bearing joint is involved.
  • Neurological Examination (for spinal TB): Crucial to assess for motor weakness, sensory deficits, reflex changes, and sphincter dysfunction.

Diagnostic Approach

History Taking

• Key Questions:
  • Duration and nature of symptoms: Insidious onset, progressive pain, stiffness, swelling.
  • Constitutional symptoms: Fever, night sweats, weight loss, fatigue, anorexia.
  • Risk factors for TB: Prior TB exposure or infection, known contact, travel history to endemic areas, country of birth.
  • Immunosuppression: HIV status, corticosteroid use, TNF-alpha inhibitors, diabetes, renal failure.
  • Past medical history: Previous surgeries, chronic conditions.
  • Specific joint symptoms: Pain pattern, aggravating/alleviating factors, functional limitation.
  • Spinal symptoms: Back pain, radicular pain, weakness, numbness, bowel/bladder changes.
• Red Flags:
  • Neurological deficits (motor weakness, sensory loss, bladder/bowel dysfunction) in spinal TB, requiring urgent neurosurgical or orthopedic consultation.
  • Rapidly progressive joint destruction or severe constitutional symptoms, indicating aggressive disease or underlying immunosuppression.
  • Presence of cold abscess or draining sinus tract.

Laboratory Tests

• First-Line:
  • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Often elevated, but non-specific. Useful for monitoring disease activity and response to treatment. Values can be significantly high (ESR >50-100 mm/hr).
  • Complete Blood Count (CBC): May show normocytic normochromic anemia (anemia of chronic disease), sometimes mild leukocytosis.
  • Tuberculin Skin Test (TST) / Interferon-Gamma Release Assay (IGRA):
    • TST (Mantoux test): Induration ≥5 mm in high-risk groups (HIV, contacts, immunocompromised) or ≥10 mm in others usually indicates exposure. False negatives can occur in immunocompromised patients or disseminated disease.
    • IGRA (QuantiFERON-TB Gold, T-SPOT.TB): More specific than TST, not affected by BCG vaccination. Both TST and IGRA indicate prior exposure to M. tuberculosis and do not distinguish between latent infection and active disease. A positive result supports the diagnosis but is not diagnostic on its own for active joint TB. A negative result does not rule out disease, especially in immunocompromised individuals.
• Confirmatory:
  • Synovial Fluid Aspiration: For joint effusions.
    • Analysis: Typically exudative, high protein, low glucose (variable, can be normal), high cell count (10,000-20,000 cells/mm³) with predominantly lymphocytes (but can be polymorphonuclear cells in early stages or acute presentations).
    • Acid-Fast Bacilli (AFB) Smear: Low sensitivity (10-30%) for joint TB, highly specific if positive.
    • Mycobacterial Culture: Gold standard for diagnosis. Cultures can take 4-6 weeks for growth. Sensitivity is better than smear (50-80%).
    • Nucleic Acid Amplification Test (NAAT/PCR): Rapid (within hours/days) and highly sensitive (70-90%) and specific for M. tuberculosis DNA. Can be performed on synovial fluid or tissue. Increasingly used as a primary diagnostic tool.
  • Tissue Biopsy (Synovial Biopsy or Bone Biopsy): Often necessary and the most definitive diagnostic method.
    • Obtained via arthroscopy, open surgery, or CT-guided needle biopsy.
    • Histopathology: Presence of characteristic caseating granulomas with epithelioid cells, lymphocytes, and Langhans giant cells. Non-caseating granulomas may also be seen.
    • AFB Smear and Culture: Performed on tissue sample; higher yield than synovial fluid.
    • NAAT/PCR: Also performed on tissue.
  • Drug Susceptibility Testing (DST): Essential for all positive cultures to guide treatment, especially in endemic areas or if drug resistance is suspected.
• Monitoring:
  • ESR/CRP: Trend towards normalization indicates treatment response.
  • Liver function tests (LFTs), Renal function tests, Uric acid: To monitor for anti-tubercular drug toxicity (hepatotoxicity, renal impairment with pyrazinamide, hyperuricemia).
  • Ocular examination: Baseline and periodic monitoring for Ethambutol-induced optic neuritis.

Imaging

• Recommended:
  • Plain Radiographs (X-rays): Initial imaging study. Early changes may be subtle or absent. Characteristic late features include:
    • Phemister's Triad: Juxta-articular osteoporosis, peripheral erosions, and gradual narrowing of joint space.
    • Soft tissue swelling, effusions.
    • Osteopenia.
    • Cystic lesions in bone.
    • Absence of periosteal reaction in early stages (unlike pyogenic osteomyelitis).
    • In spinal TB: vertebral body destruction, collapse, kyphosis, disc space narrowing (often less severe than bony involvement), paraspinal abscess (fusiform shadow).
  • Computed Tomography (CT) Scan: Superior to X-ray for defining bony destruction, sequestra, cortical erosions, and extent of abscess formation (especially paraspinal and psoas abscesses). Excellent for evaluating spinal involvement and canal compromise.
  • Magnetic Resonance Imaging (MRI): The most sensitive imaging modality for early detection of changes and assessment of soft tissue involvement.
    • Shows synovial thickening and enhancement, cartilage destruction, bone marrow edema, small effusions, and precise extent of cold abscesses.
    • Crucial for assessing neural compression and spinal cord involvement in Pott's disease.
    • Can differentiate TB from other inflammatory conditions more effectively.
• Advanced:
  • Bone Scan (Technetium-99m): Shows increased uptake in active inflammatory lesions but is non-specific and cannot differentiate TB from other infections or inflammatory conditions. Useful for identifying multifocal disease.
  • Positron Emission Tomography-CT (PET/CT): May be used in complex cases to identify active sites of infection, differentiate active disease from fibrotic lesions, and monitor treatment response. High metabolic activity (FDG uptake) correlates with active inflammation.

Management

Acute Management

• Immediate:
  • Pain control: Analgesics (NSAIDs, opioids if necessary).
  • Joint Rest/Immobilization: Splinting or casting to reduce pain, inflammation, and prevent further destruction, especially in painful peripheral joints. For spinal TB, bed rest or spinal bracing if unstable or painful.
• Stabilization:
  • Initiation of Anti-Tubercular Therapy (ATT): Once diagnosis is strongly suspected or confirmed, start ATT promptly.
  • Nutritional support: Address malnutrition.
• Emergency:
  • Spinal TB with Neurological Deficits: This is a medical and surgical emergency. Requires urgent consultation with a neurosurgeon or orthopedic spine surgeon for potential surgical decompression of the spinal cord and stabilization of the spine, in conjunction with immediate initiation of ATT.

Chronic Management

• Pharmacological:
  • Standard Multi-Drug Anti-Tubercular Therapy (ATT): This is the cornerstone of treatment. Regimen and duration differ from pulmonary TB.
    • Initial Intensive Phase: 2 months of four drugs:
      • Isoniazid (INH): 5 mg/kg/day (max 300 mg/day)
      • Rifampicin (RIF): 10 mg/kg/day (max 600 mg/day)
      • Pyrazinamide (PZA): 25 mg/kg/day (max 2000 mg/day)
      • Ethambutol (EMB): 15 mg/kg/day (max 1000 mg/day)
    • Continuation Phase: 7-10 months of two drugs:
      • Isoniazid (INH): 5 mg/kg/day (max 300 mg/day)
      • Rifampicin (RIF): 10 mg/kg/day (max 600 mg/day)
    • Total Duration:
      • For most bone and joint TB: 9-12 months.
      • For severe spinal TB with neurological involvement or large abscesses: 12-18 months may be recommended by some guidelines to ensure complete eradication and prevent relapse. Always adhere to national and international guidelines.
  • Drug Susceptibility Testing (DST): If drug resistance is suspected (e.g., patient from high MDR-TB prevalence area, treatment failure, known contact with resistant TB), DST results guide modification of the regimen with second-line anti-TB drugs.
  • Directly Observed Therapy (DOT): Recommended to ensure adherence and completion of treatment, crucial for preventing drug resistance and relapse.
  • Corticosteroids: Role is controversial. May be considered in spinal TB with severe neurological deficit or profound inflammatory response, but typically not for peripheral joint TB. If used, it is usually short-term (e.g., 2-4 weeks) and with close monitoring.
• Non-pharmacological:
  • Joint immobilization: Continued for several weeks to months, until pain and inflammation subside and healing progresses. For spinal TB, bracing or casts may be used to provide stability and prevent deformity.
  • Physiotherapy and Rehabilitation: Initiated after the acute inflammatory phase subsides and pain improves. Essential to restore joint mobility, strengthen muscles, and improve functional outcomes. Gradual weight-bearing for lower limb joints.
  • Nutritional support: Essential for healing and recovery.
  • Surgical Intervention:
    • Debridement and Drainage: For large cold abscesses, sequestra, or extensive necrotic tissue not responding to ATT.
    • Joint Salvage: Arthroscopic or open debridement, synovectomy.
    • Stabilization: Spinal fusion for unstable spinal TB, or if neurological deficit present.
    • Reconstructive Surgery: Arthrodesis (joint fusion) for severe joint destruction and instability, or arthroplasty (joint replacement) in selected cases after successful completion of ATT and confirmation of disease inactivity, especially for the hip or knee.
• Monitoring:
  • Clinical response: Improvement in pain, swelling, constitutional symptoms, range of motion.
  • Inflammatory markers: Regular monitoring of ESR and CRP (e.g., monthly initially, then every 2-3 months) to track treatment response. Normalization is a good sign.
  • Radiological follow-up: Repeat X-rays, CT, or MRI at 3-6 month intervals to assess bone healing, joint space, resolution of abscesses, and identify complications.
  • Drug toxicity monitoring: Regular LFTs (every 2-4 weeks initially), renal function, uric acid. Ocular exams for EMB.
  • Adherence: Assess medication adherence at every visit.

Treatment Algorithms

• First-Line:
  1. Diagnosis Confirmation: Clinical suspicion + imaging + laboratory tests (ESR/CRP, TST/IGRA). Definitive diagnosis requires positive culture, NAAT, or characteristic histopathology from biopsy.
  2. Initiate ATT: Standard 4-drug regimen (2HRZE) for 2 months.
  3. Continue ATT: 2-drug regimen (HR) for 7-16 months, based on site and severity. Total duration 9-18 months.
  4. Surgical consideration: For neurological deficits (spinal TB), large abscesses, severe joint destruction, or diagnostic uncertainty. Surgical debridement/stabilization as an adjunct to ATT.
  5. Rehabilitation: Physical therapy and joint protection.
• Second-Line:
  1. Drug Resistance Suspected/Confirmed: Based on contact history, prior treatment failure, or positive DST.
  2. Regimen Modification: Use of second-line anti-TB drugs (e.g., fluoroquinolones like levofloxacin/moxifloxacin, injectables like amikacin/streptomycin, bedaquiline, delamanid, clofazimine, cycloserine, para-aminosalicylic acid), guided by DST.
  3. Treatment Duration: Longer (18-24 months or more) and more complex regimens, often with more side effects.
• Refractory Cases:
  1. Re-evaluate Diagnosis: Confirm it is still active TB, rule out other causes of persistent symptoms (e.g., non-union, chronic pain, secondary infection, treatment-induced side effects).
  2. Assess Adherence: Ensure compliance with DOT.
  3. Rule out Drug Resistance: Repeat DST if not done or if resistance pattern may have changed.
  4. Surgical Intervention: Consider extensive surgical debridement, joint fusion, or salvage procedures if conservative management fails and there's significant local disease.
  5. Nutritional Status: Optimize general health and nutrition.

Complications

• Common:
  • Chronic Pain: Due to persistent inflammation, joint destruction, or neural compression.
  • Joint Stiffness and Restricted ROM: Leading to functional limitation.
  • Deformity: Fixed flexion deformities, subluxation, kyphosis (spinal TB), scoliosis.
  • Muscle Atrophy: Around the affected joint due to disuse.
  • Cold Abscess: Formation of sterile, fluctuant collections of caseous material.
  • Sinus Tract Formation: Chronic draining fistulae from cold abscesses to the skin surface, increasing risk of secondary bacterial infection.
• Serious:
  • Neurological Deficits (Spinal TB): Paraplegia, paraparesis, sensory loss, cauda equina syndrome due to spinal cord or nerve root compression. This is the most severe complication of spinal TB.
  • Pathological Fractures: In weakened bones, especially vertebrae or weight-bearing joints.
  • Secondary Bacterial Infection: Of cold abscesses or sinus tracts.
  • Amyloidosis: A rare, long-term complication of chronic inflammation, particularly if treatment is delayed or inadequate.
  • Disseminated TB: Spread of TB to other organs if not adequately treated.
• Long-term:
  • Permanent Joint Destruction and Disability: If treatment is delayed or ineffective, leading to significant functional impairment.
  • Limb Length Discrepancy: Especially if growth plates are involved in children.
  • Fixed Spinal Deformity: Severe kyphosis (gibbus) after spinal collapse.
  • Recurrence: If treatment is incomplete or drug resistance develops.

Prognosis

• Factors:
  • Early Diagnosis and Prompt Treatment: The most critical factor for a good outcome, minimizing joint destruction and complications.
  • Extent of Disease at Presentation: Less extensive disease with minimal joint/bone destruction has a better prognosis.
  • Presence of Neurological Complications: In spinal TB, neurological deficits significantly worsen prognosis for functional recovery. Complete neurological recovery is less likely once severe compression has occurred.
  • Compliance with Anti-Tubercular Therapy: Good adherence is essential to prevent drug resistance and relapse.
  • Drug Resistance: MDR-TB and XDR-TB significantly complicate treatment and worsen prognosis.
  • Immune Status of Patient: Immunocompromised patients (e.g., HIV-positive) are at higher risk of disseminated disease, drug toxicity, and treatment failure.
  • Adequacy of Surgical Intervention: When indicated, proper surgical intervention improves outcome, especially in spinal TB.
• Survival: Generally good with appropriate multi-drug ATT for isolated joint TB. Mortality is low for non-spinal bone/joint TB. However, severe spinal TB with neurological complications can have higher morbidity and, rarely, mortality.
• Quality of Life: Can be significantly impaired by residual pain, stiffness, deformity, and functional limitations, especially if permanent joint damage occurs. Early rehabilitation and physical therapy are crucial for optimizing long-term quality of life.

Prevention

• Primary: Preventing initial M. tuberculosis infection or progression to active disease.
  • BCG Vaccination: Given in high-burden countries, primarily to protect children against severe forms of TB (miliary TB, TB meningitis). Its efficacy against bone/joint TB is not as strong or consistent as against severe disseminated forms.
  • Public Health Measures: Early diagnosis and effective treatment of active pulmonary TB cases (source control), contact tracing, improved housing, nutrition, and sanitation to reduce transmission.
  • Infection Control: In healthcare settings.
• Secondary: Early detection and prompt treatment to prevent complications or progression.
  • Screening for Latent TB Infection (LTBI): In high-risk individuals (e.g., close contacts of active TB cases, immunocompromised patients, immigrants from high-burden countries). Treatment of LTBI with INH (e.g., 9 months) or rifapentine/INH (e.g., 3 months) can prevent progression to active disease, including joint TB.
  • High Index of Suspicion: For joint TB in endemic areas or in patients with risk factors, even with atypical presentations.
• Tertiary: Preventing complications and recurrence in patients already diagnosed.
  • Adherence to full course of ATT: Crucial to prevent relapse and development of drug resistance.
  • Physical Rehabilitation: To minimize long-term functional impairment and improve quality of life.
  • Monitoring for Recurrence: Especially in incompletely treated cases or immunocompromised patients.

Special Populations

• Pediatric:
  • Higher risk of dissemination: Children, especially young ones, have less developed immune systems and are more prone to hematogenous spread.
  • Atypical presentation: Symptoms can be subtle and non-specific, leading to diagnostic delays.
  • Growth Plate Involvement: Can lead to growth disturbances and limb length discrepancies.
  • Drug Dosages: Weight-based dosing for ATT. Generally well-tolerated.
  • Spinal TB: Relatively common in children.
• Geriatric:
  • Atypical Presentation: Less prominent constitutional symptoms, often mimicking degenerative joint disease.
  • Comorbidities: Polypharmacy and underlying health conditions can increase risk of ATT drug interactions and side effects (e.g., hepatotoxicity, optic neuritis).
  • Drug Dosage Adjustment: May be required for renal or hepatic impairment.
  • Higher Mortality: If diagnosis and treatment are delayed, especially with significant comorbidities.
• Pregnancy:
  • Diagnosis: Imaging (X-rays with abdominal shielding, MRI generally safe), diagnostic biopsies are acceptable.
  • Treatment: Rifampicin, Isoniazid, and Ethambutol are generally considered safe during pregnancy. Pyrazinamide's safety in the first trimester is debated but often included if multidrug resistance is suspected or disease is severe. Streptomycin is contraindicated due to ototoxicity in the fetus.
  • Breastfeeding: All first-line drugs are safe during breastfeeding, with minimal amounts excreted in milk.
• Comorbidities:
  • HIV Infection:
    • Increased risk of TB, including extrapulmonary and disseminated forms.
    • Higher risk of drug resistance.
    • Increased risk of drug-drug interactions with antiretroviral therapy (ART), particularly Rifampicin's interaction with protease inhibitors and non-nucleoside reverse transcriptase inhibitors. Adjustments to ART or ATT regimens may be necessary.
    • Immune Reconstitution Inflammatory Syndrome (IRIS): Can occur when ART is initiated in HIV-TB co-infected patients, leading to paradoxical worsening of symptoms. Management involves continued ATT and ART, sometimes with corticosteroids.
  • Diabetes Mellitus: Increased risk of TB, slower response to treatment, higher risk of relapse. Glycemic control is important.
  • Chronic Kidney Disease (CKD) / End-Stage Renal Disease (ESRD): Dose adjustment for Ethambutol and Pyrazinamide (and sometimes Isoniazid) is crucial due to renal excretion. Hemodialysis removes INH and PZA, so dosing often needs to be post-dialysis.
  • Liver Disease: Increased risk of hepatotoxicity with first-line ATT drugs, especially Isoniazid and Rifampicin. Close LFT monitoring and potentially alternative regimens are necessary.

Clinical Pearls

• Diagnostic:
  • Always consider TB in chronic, insidious onset monoarticular arthritis, especially in endemic areas or in immunocompromised patients, even without constitutional symptoms or known pulmonary TB.
  • "Cold abscess" or "cold swelling" (absence of significant warmth/erythema despite inflammation) is a classic but not always present sign.
  • Biopsy is King: Histology showing caseating granulomas, positive culture, or NAAT on synovial fluid/tissue is the definitive diagnostic method. AFB smear on fluid/tissue has low sensitivity.
  • Disc space involvement is characteristic of TB spondylitis, unlike pyogenic spondylitis which primarily affects the vertebral bodies.
  • A negative TST/IGRA does not rule out active TB, particularly in immunocompromised patients.
• Treatment:
  • ATT is the cornerstone: Surgical intervention is usually adjunctive to medical therapy, not a substitute.
  • Longer duration of ATT (9-18 months) is generally required for bone and joint TB compared to pulmonary TB.
  • Adherence is paramount: Emphasize DOT to ensure completion and prevent resistance.
  • Early and aggressive rehabilitation is crucial to maximize functional recovery and prevent long-term disability.
• Pitfalls:
  • Delayed Diagnosis: Due to insidious onset and non-specific symptoms, leading to irreversible joint damage and complications. Often mistaken for degenerative arthritis, rheumatoid arthritis, or septic arthritis.
  • Incomplete Treatment: Stopping ATT too early due to symptom improvement, leading to relapse and drug resistance.
  • Misinterpretation of Imaging: Early X-rays can be normal. MRI is superior for early detection but not always readily available.
  • Lack of Biopsy: Relying solely on non-specific tests (ESR, CRP, TST/IGRA) without obtaining tissue or fluid for definitive diagnosis.
  • Missing neurological complications: Especially in spinal TB, delayed recognition of spinal cord compression can lead to permanent paralysis.

Recent Updates

• Guidelines:
  • WHO Global TB Report (annual): Provides epidemiological updates and treatment recommendations, including for extrapulmonary TB.
  • CDC (Centers for Disease Control and Prevention) and ATS (American Thoracic Society) / IDSA (Infectious Diseases Society of America) Guidelines: Updated recommendations on diagnosis and management of TB, including specific considerations for extrapulmonary sites. Recent focus on shorter LTBI regimens and new drugs for drug-resistant TB.
• Evidence:
  • Shorter Regimens: While 6-month regimens are now standard for drug-susceptible pulmonary TB, evidence for routinely shortening regimens for bone and joint TB (especially spinal TB) to less than 9-12 months is still emerging and not universally adopted. Most guidelines still recommend longer durations due to the paucibacillary nature and difficulty of drug penetration.
  • Role of Surgery: Ongoing research on precise indications and timing of surgical intervention for spinal TB, especially the debate between conservative management versus surgical decompression for neurological deficits and stability. The trend is towards surgical intervention for instability, severe deformity, or neurological compromise unresponsive to ATT.
  • Newer Diagnostic Methods: Continued improvement and wider availability of rapid molecular diagnostic tests (e.g., GeneXpert, TB-LAM for HIV-positive individuals) for early and accurate diagnosis, including on extrapulmonary samples, which are critical for prompt initiation of appropriate therapy.
• Controversies:
  • Optimal Duration of ATT: The exact optimal duration for bone and joint TB (e.g., 9, 12, or 18 months) remains a topic of debate, with some studies suggesting shorter courses may be sufficient for uncomplicated cases, while others advocate for longer courses to prevent relapse.
  • Role of Corticosteroids: The benefit of adjunctive corticosteroids in spinal TB (beyond neurological deficits) and peripheral joint TB is still not definitively established.
  • Timing of Surgical Intervention: Debate exists on early versus delayed surgery, especially for spinal TB without severe neurological deficits.

Key References

• Guidelines:
  • World Health Organization (WHO) Guidelines for Treatment of Drug-Susceptible Tuberculosis and Drug-Resistant Tuberculosis.
  • American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
  • National Institutes of Health (NIH) - National Guidelines for TB Management (country-specific).
• Studies:
  • Landmark trials on TB treatment efficacy, though specific large-scale randomized controlled trials focusing solely on bone and joint TB treatment duration are less common than for pulmonary TB. Evidence is often derived from cohort studies and expert consensus.
  • Studies on surgical management outcomes for spinal TB.
• Reviews:
  • Comprehensive reviews published in major infectious disease, orthopedic, and rheumatology journals (e.g., Lancet Infectious Diseases, Clinical Infectious Diseases, Spine, Journal of Bone and Joint Surgery).
  • UpToDate, Harrison's Principles of Internal Medicine, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.